Triplex-Forming Oligonucleotides Target HER2 Amplification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies targeting HER2 gene amplification face challenges due to drug resistance, especially in p53-independent cancers which are aggressive and resistant to traditional chemotherapies.
Innovation Solution
The use of triplex-forming oligonucleotides (TFOs) that target specific polypurine sites in the amplified HER2 gene to induce p53-independent apoptosis in cancer cells, utilizing their ability to form triplex structures that cause DNA damage and trigger apoptosis, even in cells lacking functional p53.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional chemotherapeutic drugs are used to target HER2 gene amplification, then cancer cell proliferation is inhibited, but drug resistance develops especially in p53-independent cancers
Solution Approach 1:
The patent introduces triplex-forming oligonucleotides (TFOs) as an intermediary molecular structure that binds to the major groove of HER2 gene DNA. These TFOs form stable triplex structures that physically block transcription and induce DNA damage, serving as a mediator between the therapeutic goal and the cellular machinery, thereby overcoming resistance to traditional protein-targeting chemotherapies
Solution Approach 2:
The patent replaces the mechanical/protein-targeting approach of traditional chemotherapy with a nucleic acid-based approach. Instead of targeting overexpressed HER2 proteins, the invention uses TFOs to directly target and bind to the HER2 gene DNA sequence, substituting the therapeutic mechanism from protein-ligand interaction to nucleic acid hybridization and triplex formation
2Reliability
If p53-dependent apoptosis pathways are targeted, then cancer cell death is induced in p53-functional cancers, but the approach fails in p53-independent cancers
Solution Approach 1:
The patent creates a universal therapeutic approach using TFOs that can induce apoptosis through multiple mechanisms regardless of p53 status. The TFOs simultaneously block gene transcription, induce DNA damage, and trigger apoptosis through both p53-dependent and p53-independent pathways, making the therapy universally effective across different cancer types including p53-deficient cancers
Solution Approach 2:
The patent converts the harmful characteristic of p53 loss (which normally protects cancer cells from apoptosis) into a benefit by activating alternative p53-independent apoptotic pathways. The TFO-induced DNA damage and transcriptional blockade trigger apoptosis through mechanisms that do not require functional p53, thereby transforming the resistant phenotype into a vulnerable state
3Reliability
If high doses of chemotherapeutic drugs are administered to overcome resistance, then therapeutic efficacy increases, but toxicity to normal cells increases
Solution Approach 1:
The patent applies local quality by designing TFOs with sequences specifically complementary to the HER2 gene polypurine regions. This sequence-specific design ensures that TFOs selectively bind to and induce apoptosis in HER2-amplified cancer cells while leaving normal cells with non-amplified HER2 genes unaffected, achieving localized therapeutic action at the molecular level
Solution Approach 2:
The patent employs partial action by using multiple TFOs targeting different polypurine regions within the HER2 gene. This multi-target approach ensures that even if some TFO binding sites are blocked or repaired, others remain vulnerable, providing redundant therapeutic pressure that overcomes resistance without requiring excessive dosing that would harm normal cells
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively reduces the number of cancer cells by inducing apoptosis specifically in HER2-amplified cells, demonstrating potential as a targeted therapy that can overcome resistance to traditional treatments, particularly in p53-defective conditions.
Implementation Method 1
manipulation of the DNA damage response with triplex-forming oligonucleotides (TFOs) drives p53-independent tumor-specific induction of apoptosis
Data Source
AI summary
Disclosed herein are methods and agents for the treatment of cancer using p53-independent apoptosis to reduce the number of p53-depleted or p53-mutated cancer cells that have amplified HER2 gene. Also disclosed herein are methods and agents for the treatment of HJ-R2-positive: cancer in individuals with Li-Fraumeni Syndrome.